Genetic origin of a large family with a novel PSEN1 mutation (Ile416Thr)
Laura Ramirez Aguilar, Juliana Acosta-Uribe, Margarita M Giraldo, Sonia Moreno, Ana Baena, Diana Alzate, Rosario Cuastumal, David Aguillón, Lucía Madrigal, Amanda Saldarriaga, Alexander Navarro, Gloria P Garcia, Daniel C Aguirre-Acevedo, Ethan G Geier, J Nicholas Cochran, Yakeel T Quiroz, Richard M Myers, Jennifer S Yokoyama, Kenneth S Kosik, Francisco Lopera, Laura Ramirez Aguilar, Juliana Acosta-Uribe, Margarita M Giraldo, Sonia Moreno, Ana Baena, Diana Alzate, Rosario Cuastumal, David Aguillón, Lucía Madrigal, Amanda Saldarriaga, Alexander Navarro, Gloria P Garcia, Daniel C Aguirre-Acevedo, Ethan G Geier, J Nicholas Cochran, Yakeel T Quiroz, Richard M Myers, Jennifer S Yokoyama, Kenneth S Kosik, Francisco Lopera
Abstract
Introduction: A small percentage of Alzheimer's disease (AD) cases are caused by genetic mutations with autosomal dominant inheritance. We report a family with a novel variant in PSEN1.
Methods: We performed clinical and genetic evaluation of 93 related individuals from a Colombian admixed population. 31 individuals had whole-genome sequencing.
Results: Genetic analysis revealed a missense variant in PSEN1 (NM_000021.3: c.1247T>C p.Ile416Thr), which originated on an African haplotype and segregated with AD logarithm of the odds score of 6. Their clinical phenotype is similar to sporadic AD except for earlier age at onset: the mean age at onset for mild cognitive impairment was 47.6 years (standard deviation 5.83) and for dementia 51.6 years (standard deviation 5.03).
Discussion: Ile416Thr is a novel pathogenic variant that causes AD in the sixth decade of life. The history of the region that included slave importation and admixtures within a confined geographic locale represents a "mini-population bottleneck" and subsequent emergence of a rare dominant mutation.
Trial registration: ClinicalTrials.gov NCT01998841.
Keywords: Admixture in Latin America; Autosomal dominant Alzheimer's disease; Founder effect; Genetic Bottleneck; Genetic drift; Phenotype genotype correlation; Presenilin 1.
Conflict of interest statement
CONFLICTS OF INTEREST
The authors declare no conflicts of interest on the research, authorship, and/or publication of this study. Francisco Lopera, M.D. and Margarita Giraldo, M.D. are investigators at API-Colombia clinical trial for genetic Alzheimer’s Disease (NCT01998841).
Copyright © 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Figures
Source: PubMed